TOR inhibitors following heart transplant


Authors: L. Špinarová
Published in: Kardiol Rev Int Med 2011, 13(1): 44-47
Category: From Heart Failure to Heart Transplantation

Overview

This is an overview of the use of new immuno­suppressive medication – TOR inhibitors – including everolimus and sirolimus on patients following heart transplants. It is possible to administer these medicaments de novo or to switch from existing therapy. Indicators for a switch are calcineurin nephropathy, vasculopathies, malignities, myopathies and neurotoxicity. These medicaments thus increase the options for immunosuppression, with treatment administered according to any accompanying illnesses suffered by patients.

Keywords:
transplants – TOR inhibitors – immunosuppression


Sources

1. Kurian KC, Addisu A. Sirolimus: A novel immunosupressive drug in heart transplantation. Rec Patents on Cardiovasc Drug Discovery 2009; 4: 187–191.

2. Radovancevic B, El-Sabrout R, Thomas C et al. Rapamycin reduces rejection in heart transplant recipients. Transplantation Proceedings 2001; 33:  3221–3222.

3. Rothenburger M, Zuckermann A, Bara C et al. Certican Consensus Study Group. Recommendations for the use of everolimus (Certican) in heart transplantation: ­results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007; 26: 305–311.

4. Meiser B, Kaczmarek I, Muller M et al. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplantat 2007; 26: 598–603.

5. Mueller M, Meiser B, Groetzner J et al. Sirolimus in combination with tacrolimus for primary immunosuppression after heart transplantation. J Heart Lung Transplant 2004; 23: S46.

6. Radovancevic B, Thomas CD, Ford EL et al. Comparison of rapamycin and mycophenolate mofetil therapy in heart transplant recipients treated with tacrolimus. Heart transplantation Abstracts: 527.

7. Keogh A, Richardson M, Ruygok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 2004; 110: 2694–2700.

8. Kobashigawa JA, Muller LW, Russell SD et al. Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377–1386.

9. Eisen H, Kobashigawa H, Starling RC et al. 24-month safety results of a randomized, multicenter, double-blind study of everolimus vs azathioprine in de novo heart transplant recepients. J Heart Lung Transpl 2004; 23 (Suppl. 2): S45.

10. Haverich A, Tuzcu EM, Vigano M et al. ­Everolimus in de novo cardiac transplant recipients. 24-month ­follow-up. J Heart Lung Transpl 2003; 22 (Suppl. 1): S140–S141.

11. Tuzcu EM, Kobashigawa JA, Eisen HJ et al. Favorable effect of everolimus on cardiac allograft vasculopathy is maintaned through 24 months. J Heart Lung Transpl 2004; 23 (Suppl 2): S51.

12. Snell GI, Levvey BJ, Chin W et al. Rescue therapy: A role for sirolimus in lung and heart transplant reci­pients. Transpl Proc 2001; 33: 1084–1085.

13. Špinarová L. Transplantace srdce. Cor et Vasa 2008: 50: 133–138.

14. Málek I. Transplantace srdce. Postgrad Med 1999; 1: 95–100.

15. Delgado JF, Crespo MG, Manito N et al. Usefulness of sirolimus as rescue therapy in heart transplant reci­pients with renal failure: Analysis of the Spanish multicenter observational study (RAPACOR). Transplant Proc 2009; 41: 3835–3837.

16. Potena L, Bianchi IG, Magnani G et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomised study. Transplantation 2010; 89: 263–265.

17. Snell GI, Levvey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540–546.

18. Groetzner J, Kaczmarek I, Muller M et al. Calcineurin-inhibitor-free immunosuppression with mycophenolatmofetil and sirolimus after cardiac transplantation is safe and improves renal function significantly: 1 year follow up. Transplantation 2004; 78 (Suppl. 1): S161.

19. Lehneman JB, Smallwood GA, Corby DÁ et al. Retrospective review of sirolimus use for chronic rejection and renal dysfunction in heart transplant recipients. Am J Transpl 2004; 4 (Suppl. 8): S177.

20. Hunt J, Lerman M, Dewey T et al. Conversion to ­sirolimus lessens renal dysfunction in heart transplant patients. J Heart Lung Transpl 2004; 23 (2S): 113.

21. Gude E, Gullestad L, Arora S et al. Benefit of early conversion from CNI-based to everolimus based immuno­suppression in heart transplantation. J Heart Lung Transplant 2010; 29: 641–647.

22. Delgado JF, Manito N, Segovia J et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev 2009; 23: 69–79.

23. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48–53.

24. Eisen HJ, Tuzcu EM, Dorent R et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant reci­pients. N Engl J Med 2003; 349: 847–858.

25. Špinarová L, Hude P, Krejčí J et al. Osud pacientů přežívajících deset let po transplantaci srdce se zřetelem k výskytu maligního onemocnění. Cor Vasa 2009; 51: 415–418.

26. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581–589.

27. Schena FP, Pascoe MD, Alberu J et al. Sirolimus CONVERT Trial Study Group. Conversion from calci­neurin inhibitors or sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233–242.

28. Wasywich CA, Croxson MC, van Doomum GJ et al. Sirolimus for Kaposi’s sarcoma. J Heart Lung Transplant 2006; 25: 726–729.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account